MedPath

HOPE for Small grafts in Living Donor Liver Transplantatio

Not Applicable
Conditions
Health Condition 1: - Health Condition 2: O- Medical and Surgical
Registration Number
CTRI/2023/06/053391
Lead Sponsor
Mohamed Rela
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Donor criteria:

1.Any living liver donor used for transplantation at Dr. Rela institute within the study period

2.Any type of donation surgery (open, robotic,..)

3.Any liver lobe (right, left)

4.GRWR <0.7 (study arm II: cold storage with 2hrs HOPE) and =0.7 (Study arm I: standard cold storage)

Recipient Criteria:

1.Adult recipient (=18years of age) of living related liver transplantation at Dr. Rela Institute

2.Primary liver transplantation

3.Donor-recipient ABO compatible or incompatible

4.Lab MELD of =25points

5.Recipient with any chronic liver disease with or without cirrhosis with or without liver tumour (HCC, or other)

6.Consented recipient

Exclusion Criteria

1.Recipient listed due to acute or subacute liver failure

2.Recipient listed for retransplantation

3.Recipients with known grade III or IV portal vein thrombosis

4.Recipients with combined transplantation (e.g., liver + kidney, liver + any other organ)

Recipients with lab MELD >25points

5.Recipients with sepsis (ICU requirement) at the time of transplantation

6.Recipients with ventilation at time of transplantation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary Endpoint: <br/ ><br>SFSS (Small for size Syndrome) , EAD (Early Allograft Dysfunction )Timepoint: 3 months
Secondary Outcome Measures
NameTimeMethod
1.Need for intraoperative flow modulation (surgical: Splenic Artery Ligation, Splenic Embolisation, Porto caval-shunt, pharmacological…) or postop interventions <br/ ><br>2.Intraoperative RBC, FFP trasnfusions <br/ ><br>3.Lactate end of Orthotopic Liver Trasnplantation(OLT), pharmacological support end of OLT <br/ ><br>4.HOPE perfusate: FMN, NADH, oxygenation <br/ ><br>5.ICU, hospital stay <br/ ><br>6.Transaminases 1st week including peak <br/ ><br>7. INR 12 and 24hrs and day 7 after OLT <br/ ><br>8.Lactate 6, 12, 24hrs after OLT <br/ ><br>9.Bilirubin day 7 <br/ ><br>10.AKI rate, need for dialysis/CVVH and duration <br/ ><br>11.Pharmacological support <br/ ><br>12.Biliary, vascular com1plications <br/ ><br>13.Sepsis/infection <br/ ><br>14.Major complication & CCI(comprehensive Complication Index in hospital, 3m, 12m after OLT <br/ ><br>15. Graft/patient survival within 1y after OLT <br/ ><br>Timepoint: in hospital, 3, 6, 9, 12 months
© Copyright 2025. All Rights Reserved by MedPath